I’m working on buying stocks for Intercytex when I ran into the article below. It’s dated, but I couldn’t help but think of The Game…
Intercytex confident despite losses
Intercytex Group plc has blamed a fall in turnover during 2006 on sustained R&D spending, but pointed to a number of “value generating events” in 2007.
The cell therapy company, focused on high impact treatments to restore and regenerate skin and hair, listed on AIM in February 2006, raising £13.7 million (net of expenses).
In the year ended 31 December 2006, it reported a loss before tax of £9.2 million, up from £7.2 million in 2005.
Nick Higgins, chief executive of Intercytex, commented: “Over the past 12 months we have completed a considerable amount of commercial and clinical preparatory work. The foundations have been laid for a series of value generating events in 2007 as clinical trial data is reported on all four of our products and the first sales of our facial rejuvenation product, Vavelta, are achieved.”
Friday, March 23, 2007